Trial Profile
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EMPA-REG METSU; EMPA-REG-METSU
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 31 Jul 2018 Results of pooled analysis (see profiles: 56615, 57731, 58105, 58520 and 60013) investigating the effect of empagliflozin on aminotransferases published in the Diabetologia
- 15 Sep 2017 Results of pooled safety analysis in >12,000 patients who were randomized to Empagliflozin (10 mg, 25 mg) or placebo in 15 Phase I-III trials plus 4 extension studies, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 16 Sep 2016 Results of a pooled analysis assessing risk of bone fracture presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes